Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and potassium ion efflux, leading to inhibition of protein, DNA, and RNA synthesis, and bacterial cell death.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Complicated skin and skin structure infections (c SSSI) in adults,Staphylococcus aureus bloodstream infections (bacteremia) including right-sided infective endocarditis,Off-label: Prosthetic joint infections, osteomyelitis, vancomycin-resistant enterococcal infections
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
4-6 mg/kg intravenously every 24 hours. For Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, 6 mg/kg intravenously every 24 hours.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment (up to 28 hours in severe impairment).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Metabolism is not well characterized; minor hepatic metabolism suspected. Primarily excreted renally as unchanged drug.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal (78% unchanged in urine); biliary/fecal excretion is negligible (<6%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
92-93% bound to human plasma proteins, primarily albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.1 L/kg; low Vd indicating limited tissue distribution, primarily confined to extracellular fluid.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Not applicable (intravenous only; bioavailability is 100% by IV route).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Cr Cl ≥30 m L/min: no adjustment. Cr Cl <30 m L/min: 4-6 mg/kg intravenously every 48 hours. For patients on hemodialysis or continuous ambulatory peritoneal dialysis, administer after dialysis on dialysis days.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Children 1-6 years: 10 mg/kg intravenously every 24 hours. Children 7-17 years: 7 mg/kg intravenously every 24 hours. Maximum dose: 500 mg per dose.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment based solely on age. Use caution due to increased risk of renal impairment; adjust dose based on creatinine clearance as for adults.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
Eosinophilic pneumonia: Monitor for new onset fever, dyspnea, cough, and pulmonary infiltrates.,Peripheral neuropathy: Monitor for sensory or motor deficits.,Clostridioides difficile-associated diarrhea: Consider if diarrhea occurs.,Skeletal muscle effects: Monitor creatine phosphokinase (CPK) levels weekly; discontinue if marked elevation or myopathy symptoms.,Renal impairment: Dose adjustment required for Cr Cl <30 m L/min.,Anaphylaxis/hypersensitivity reactions: Discontinue if severe reactions occur.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to daptomycin or any component of the formulation.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No clinically significant food interactions. Take without regard to meals.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at systemic exposures up to 4 times the human dose. Risk cannot be ruled out; use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Unknown if daptomycin is excreted in human milk. Caution advised due to potential disruption of infant gut flora. No M/P ratio available.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustments recommended based on pharmacokinetic changes in pregnancy; standard dosing based on renal function and indication.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor creatine phosphokinase (CPK) weekly due to risk of myopathy; daptomycin is inactivated by pulmonary surfactant, so avoid use in pneumonia. Administer over 30 min IV. Dose adjustment required for Cr Cl <30 m L/min (including hemodialysis).
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report unexplained muscle pain, tenderness, or weakness immediately.,Complete the full course of therapy even if you feel better.,Inform your doctor if you have kidney disease or are on dialysis.,This medication is given intravenously; you may experience injection site reactions.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Concurrent use of rosuvastatin and daptomycin may increase the risk of skeletal muscle toxicity, particularly myopathy and rhabdomyolysis. Daptomycin can elevate serum creatine kinase (CK) levels and cause myopathy, while rosuvastatin, a potent HMG-CoA reductase inhibitor, also carries a risk of myotoxicity. The combination may synergistically enhance muscle damage, leading to potentially severe clinical outcomes."
"Concomitant use of pravastatin, a HMG-CoA reductase inhibitor, with daptomycin, a cyclic lipopeptide antibiotic, may increase the risk of skeletal muscle toxicity, including myopathy and rhabdomyolysis. This is due to additive or synergistic effects on skeletal muscle cells, potentially leading to elevated creatine kinase (CK) levels and muscle pain or weakness. Clinically, this interaction can result in severe muscle damage, renal impairment from myoglobinuria, and in rare cases, life-threatening rhabdomyolysis."
"The combination of fluvastatin, an HMG-CoA reductase inhibitor, and daptomycin, a lipopeptide antibiotic, may increase the risk and severity of myopathy and rhabdomyolysis due to additive muscle toxicity. Daptomycin can cause skeletal muscle effects such as elevated creatine kinase (CK) and myalgia, while statins are known to induce myopathy via mitochondrial dysfunction and altered cellular signaling. Concurrent use may potentiate these effects, leading to serious clinical outcomes including renal failure."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAPTOMYCIN IN 0.9% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and potassium ion efflux, leading to inhibition of protein, DNA, and RNA synthesis, and bacterial cell death.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAPTOMYCIN IN 0.9% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAPTOMYCIN IN 0.9% SODIUM CHLORIDE is: 4-6 mg/kg intravenously every 24 hours. For Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, 6 mg/kg intravenously every 24 hours.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAPTOMYCIN IN 0.9% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAPTOMYCIN IN 0.9% SODIUM CHLORIDE is classified as Category A/B. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at systemic exposures up to 4 times the human dose. Risk cannot be ruled ou. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.